Compare drug alternatives
Alecensa® Alternatives
Alecensa®(Alectinib Hydrochloride) | ®() |
|---|---|
Prescription Only | Prescription Only |
| Dosage & Administration | Dosage & Administration comparison data |
Administration | |
Dosing | |
Latin Shorthand | |
| Financial Assistance | Financial Assistance comparison data |
Out-Of-Pocket Costs With Copay Card | |
$5. Learn more. | |
Annual Cap | |
$25,000. Learn more. | |
Assistance Expiration | |
Generics | |
No lower-cost generic available | No lower-cost generic available |
| Physician Advisory | Physician Advisory comparison data |
Adverse Reactions | |
The most common adverse reactions (incidence ≥20%) were fatigue,
constipation, edema, myalgia, and anemia.. Learn more. | |
Mechanism of Actions (MoA) | |
Kinase inhibitors. Learn more. | |
Special Populations | |
Can ALECENSA be used during pregnancy? No, ALECENSA can cause fetal harm when administered to a pregnant woman. It is advised to avoid using ALECENSA during pregnancy and advise pregnant women of the potential risk to a fetus. Can ALECENSA be used during lactation? No, there are no data on the presence of alectinib or its metabolites in human milk, the effects of alectinib on the breastfed infant, or its effects on milk production. It is advised to not breastfeed during treatment with ALECENSA and for 1 week after the final dose. Should females and males of reproductive potential use contraception during treatment with ALECENSA? Yes, females of reproductive potential should use effective contraception during treatment with ALECENSA and for 1 week after the final dose. Males with female partners of reproductive potential should also use effective contraception during treatment with ALECENSA and for 3 months following the final dose. Is ALECENSA safe for pediatric use? The safety and effectiveness of ALECENSA in pediatric patients have not been established. Is ALECENSA safe for geriatric use? Clinical studies of ALECENSA did not include a sufficient number of subjects aged 65 and older to determine whether they respond differently from younger subjects. Is ALECENSA safe for use in patients with renal or hepatic impairment? No dose adjustment is recommended for patients with mild or moderate renal impairment or mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. However, the safety of ALECENSA in patients with severe renal impairment (creatinine clearance less than 30 mL/min) or end-stage renal disease and severe hepatic impairment (Child-Pugh C) is unknown. | |